Selection of Tissue Factor-Deficient Cell Transplants as a Novel Strategy for Improving Hemocompatibility of Human Bone Marrow Stromal Cells

Conclusion: We demonstrate that plasma-based thromboelastometry provides a reliable tool to detect pro-coagulant activity of therapeutic cells. Selecting TF-deficient BMSC is a novel strategy for improving cell therapy applicability by reducing cell dose-dependent IBMIR risk. The particularly strong pro-coagulant activity of UC and WAT preparations sounds an additional note of caution regarding uncritical systemic application of stromal cells, particularly from non-hematopoietic extravascular sources.

Source: Theranostics - June 20, 2018 Category: Molecular Biology Authors: Michaela Oeller, Sandra Laner-Plamberger, Sarah Hochmann, Nina Ketterl, Martina Feichtner, Gabriele Brachtl, Anna Hochreiter, Cornelia Scharler, Lara Bieler, Pasquale Romanelli, Sebastien Couillard-Despres, Elisabeth Russe, Katharina Schallmoser, Dirk Str Tags: Research Paper Source Type: research